{
  "id": "5c72ba807c78d69471000076",
  "type": "yesno",
  "question": "Is avelumab effective for bladder cancer?",
  "ideal_answer": "Yes, avelumab is effective treatment of bladder cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29069302",
    "http://www.ncbi.nlm.nih.gov/pubmed/29606979",
    "http://www.ncbi.nlm.nih.gov/pubmed/28864844",
    "http://www.ncbi.nlm.nih.gov/pubmed/28214651",
    "http://www.ncbi.nlm.nih.gov/pubmed/29644490",
    "http://www.ncbi.nlm.nih.gov/pubmed/29416316",
    "http://www.ncbi.nlm.nih.gov/pubmed/29540084",
    "http://www.ncbi.nlm.nih.gov/pubmed/29784744",
    "http://www.ncbi.nlm.nih.gov/pubmed/28982750",
    "http://www.ncbi.nlm.nih.gov/pubmed/29103968",
    "http://www.ncbi.nlm.nih.gov/pubmed/28493171"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29103968",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Six drugs including one CTLA-4 blocker (ipilimumab), two PD-1 blockers (nivolumab and pembrolizumab) and three PD-L1 blockers (atezolizumab, avelumab and durvalumab) are approved for the treatment of different types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and Merkel cell cancer as well as hematological tumors such as classic Hodgkin's lymphoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069302",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Food and Drug Administration has already approved a number of checkpoint inhibitors such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) monoclonal antibodies including ipilimumab; anti-PD-1 monoclonal antibodies including nivolumab and pembrolizumab; anti-PD-L1 antibodies including atezolizumab, avelumab, and durvalumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29416316",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Five immune CPI have recently been approved for aUC/mUC by the US Food and Drug Administration (FDA) including atezolizumab, nivolumab, pembrolizumab, durvalumab and avelumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606979",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RECENT FINDINGS: Since May 2016, five different agents targeting the PD-1/PD-L1 pathway (atezolizumab, pembrolizumab, nivolumab, avelumab, durvalumab) have received FDA approval for the treatment of aUC in the platinum-refractory setting, while pembrolizumab and atezolizumab are FDA-approved for cisplatin-ineligible patients in the first-line setting.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29644490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avelumab for the treatment of urothelial cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29540084",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Avelumab, a PD-1 ligand (PD-L1) inhibitor, is currently being investigated for the treatment of UC. Areas covered: This article will review the pharmacological characteristics of avelumab, the efficacy studies which led to its approval, its safety profile, as well as its place within the management of urothelial carcinoma with immunotherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29540084",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert commentary: Avelumab has shown promising antitumor activity and a manageable safety profile in patients with UC. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29540084",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Atezolizumab is the only member of this class currently approved for the treatment of bladder cancer, but nivolumab, pembrolizumab, durvalumab, and avelumab all have positive results for this indication, and approvals are anticipated in the near future.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28214651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28982750",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab are promising PD-1/PD-L1 blockade drugs under investigation that will redefine the standard of care for bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493171",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monoclonal antibodies that target programmed cell death protein 1 (PD-1), including Nivolumab and Pembrolizumab, and its ligand, PD-L1, including Atezolizumab, Durvalumab, Avelumab, have all been investigated and approved in the setting of metastatic refractory urothelial cancer (Gupta et al.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28864844",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Six drugs including one CTLA-4 blocker (ipilimumab), two PD-1 blockers (nivolumab and pembrolizumab) and three PD-L1 blockers (atezolizumab, avelumab and durvalumab) are approved for the treatment of different types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and Merkel cell cancer as well as hematological tumors such as classic Hodgkin's lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069302",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab are among the exciting recent novel therapeutic advances gaining approvals by the FDA for treatment of advanced-stage urothelial carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29784744",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}